Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
Your wait is over now
Athletes use it to bounce back from injuries faster
AOD 9604 is hypothesized to potentially induce lipolysis without significant impacts on insulin and IGF-1 levels in laboratory models, potentially moderating risks associated with glucose intolerance in these experimental settings
Key Takeaways BPC-157 is a promising research peptide, showing encouraging preclinical results
Why Oral Bioavailability Is Lower Even though BPC-157 survives gastric acid better than most peptides, oral administration still subjects it to: First-pass metabolism the liver processes a significant portion before it reaches systemic circulation Variable absorption affected by food, stomach pH, and individual GI function Enzymatic degradation some breakdown still occurs in the intestinal tract The result is that oral BPC-157 delivers a lower and less predictable systemic dose compared to injection
US$ 27.20
US$ 29.28
US$ 20.10